In vitro study of the mechanism of intraneuronal β-amyloid aggregation in Alzheimer's disease

• Published in: Archives of physiology and biochemistry Vol. 128; no. 3; pp. 732 - 739
• Main Authors: Alsunusi, Shahad, Kumosani, Taha A., Glabe, Charles G., Huwait, Etimad A., Moselhy, Said S.
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 04.05.2022
• Subjects: aggregation; Alzheimer disease; Alzheimer Disease - metabolism; Amyloid - metabolism; Amyloid beta-Peptides - metabolism; Amyloid beta-Protein Precursor - metabolism; amyloid β-protein; Humans; Neurons - metabolism; PC12; Plaque, Amyloid - metabolism; Plaque, Amyloid - pathology; amyloid β-protein; PC12; aggregation; Alzheimer disease
• ISSN: 1381-3455; 1744-4160
• DOI: 10.1080/13813455.2020.1722707

Alzheimer's disease (AD) is atrophy of brain cells that lead to decline in the mental capacity and memory. This study investigated the mechanism which postulates that intraneuronal accumulation of amyloid aggregates for pathogenesis of AD. The PC12 cell line was used to examine the amyloid beta (Aβ) aggregation in different stages. It was found that dot-blot filter retardation assay for Ub-CTF was 0.25 and 0.2 µM for SS-CTF. In addition, incubation of SS-CTF with 200 µM Aβ-42 then bounded with an antibody directed against Aβ. It was suggested that most bound Aβ-42 in the oligomeric form. Confocal microscope showed that stained with DAPI (blue) in the neuritic plaques, APP-GFP (green) and specific monoclonal M78 (red). Aß oligomeric taken up by neurons and accumulation of misfolded Aß aggregates continue in a perinuclear location. Fluorescence intensities correlate with the priming effect observed on the Aβ (p < .001). It was concluded that a new amyloid hypothesis is promising in therapy development to reduce the incidence of disease by inhibition of intraneuronal amyloid aggregation.